Home Transmembrane Transporters CD markers

CD markers Inhibitors

Cat.No. Product Name Information Product Use Citations Product Validations
S8960 CD38 inhibitor 1 (compound 78c) CD38 inhibitor 1 (compound 78c, CD38-IN-78c, MDK-7553) is a potent inhibitor of CD38 with IC50 of 7.3 nM and 1.9 nM for human CD38 and mouse CD38, respetively.
Leukemia, 2025, 10.1038/s41375-025-02551-4
J Nanobiotechnology, 2025, 23(1):457
Cell Rep Med, 2024, 5(2):101400
S5525 SodiuM Metatungstate Sodium metatungstate (SMT) solution is an inorganic heavy liquid which is widely used in density fractionation. Sodium metatungstate (Sodium polyoxotungstates) is a potent and selective inhibitor of ecto-nucleoside triphosphate diphosphohydrolase (NTPDases, CD39) with Ki of 0.140 μM, 0.910 μM and 0.563 μM for NTPDase1, NTPDase2 and NTPDase3, respectively.
Cancer Immunol Immunother, 2024, 73(6):108
Immunology, 2022, 10.1111/imm.13493
Cancer Cell, 2021, 39(7):973-988.e9
S9867 LY-3475070 LY-3475070 is a potent, selective and orally bioavailable inhibitor of the ectoenzyme CD73 (cluster of differentiation 73, 5'-ecto-nucleotidase, 5'-NT, ecto-5'-nucleotidase).
Theranostics, 2024, 14(3):1224-1240
Immunology, 2022, 10.1111/imm.13493
S3301 Cynarin Cynarin (Cynarine) is an artichoke phytochemical that possesses a variety of pharmacological features including free-radical scavenging, antioxidant, antihistamic and antiviral activities. This compound blocks the interaction between the CD28 of T-cell receptor and CD80 of antigen presenting cells. It triggers Nrf2 nuclear translocation, restores the balance of glutathione (GSH) and reactive oxygen species (ROS), and inhibits mitochondrial depolarization.
International Journal of Molecular Medicine, 2025, 206
Int J Mol Med, 2025, 56(6)206
S0141 NQ301 NQ301 (Compound 211), an antiplatelet and antithrombotic agent, is a selective CD45 inhibitor with IC50 of 200 nM. This compound inhibits thromboxane A2 receptor (TXA2) and synthase activity in rabbit platelets.
Journal of Extracellular Vesicles, March 10, 2021, e12078
Journal of Extracellular Vesicles, 2021, e12078
J Extracell Vesicles, 2021, 10(5):e12078
S6727 AX-024 HCl AX-024 HCl blocks the interaction of the CD3ε PRS with SH3.1(Nck). This compound also inhibits IL-6, TNF-α, IFN-γ, IL-10 and IL-17A.
Cell Rep Med, 2025, S2666-3791(25)00231-9
Cell Reports Medicine, 2025, 102158
E4693New AC-73 AC-73 is a first specific, orally active and potent inhibitor of CD147. It exerts anti-proliferative effects by inducing autophagy and enhancing chemotherapeutic sensitivity in acute myeloid leukemia (AML) cells, while also inhibiting Hepatocellular carcinoma (HCC) mobility and invasion through suppression of the CD147/ERK1/2/STAT3/MMP-2 pathway, making it valuable for AML and HCC research.
S8908 AB680 AB-680 is a highly potent, reversible and selective inhibitor of CD73 (an ecto-nucleotidase), with a Ki of 4.9 pM for hCD73.
E1276 MK-0159 MK-0159 (Compound 37) is an inhibitor of CD38. This compound inhibits human, mouse, and rat CD38 (cell-free assays) with IC50 values of 22, 3, and 70 nM, respectively. It increases NAD+ (nicotinamide adenine dinucleotide) and reduces ADPR (adenosine diphosphate ribose) in whole blood and heart.
E1305 RBN013209 RBN013209 is a potent inhibitor of CD38 with an IC50 of 0.01-0.1 μM for human CD38. It can be used for the research of cancer.
E5853 SMS121 SMS121 is a potent inhibitor of CD36 with a Kd value of 5.57 µM. It impairs fatty acid uptake, as well as the viability and proliferation of acute myeloid leukemia (AML) cells, indicating its potential as a future therapeutic agent against AML.
S2632 BMS-378806 BMS-378806 (BMS 806) selectively inhibits the binding of HIV-1 gp120 to the CD4 receptor with EC50 of 0.85-26.5 nM in virus.
Commun Biol, 2025, 8(1):442
Commun Biol, 2023, 6(1):535
J Virol, 2021, 95(24):e0052921
S6347 5'-N-Ethylcarboxamidoadenosine (NECA) 5'-N-Ethylcarboxamidoadenosine (NECA, 5'-(N-Ethylcarboxamido)adenosine, Adenosine-5'N-ethylcarboxamide, 5'-Ethylcarboxamidoadenosine) is a stable, nonselective adenosine receptor agonist. It acts via multiple mechanisms including: reducing diabetes-induced oxidative stress, inhibiting gene expression of IL-18, TNF-α and ICAM-1 (intercellular adhesion molecule 1 (CD54)), and blocking activation of the JNK-MAPK pathway.
Cancer Immunology, Immunotherapy, 2023 May, 1315-1326
S7487 YYA-021 YYA-021 is a CD4-mimic HIV entry inhibitor, competitively inhibiting the interaction between gp120 and CD4.